Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required

The Food and Drug Administration (FDA) is seeking applications for clinical trials to address unmet needs in rare neurodegenerative diseases. The purpose of this funding opportunity is to support clinical trials that evaluate the efficacy and/or safety of products for new indications or changes in labeling to address these unmet needs. The FDA expects that the supported clinical trials will increase the number of approved treatments for rare neurodegenerative diseases and have a broad and positive impact on rare disease drug development. • The funding opportunity is open to a variety of applicant types, including public and state-controlled institutions of higher education, small businesses, and non-profits. • The award ceiling is $900,000 and the award floor is $650,000. • The funding instrument is a grant. • The funding activity categories include agriculture, consumer protection, and food and nutrition.